Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Operating Officer | July 21, 2020 | July 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date July 21, 2020 · Filed July 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 220,867 |
Ending reported balance
After 2020-07-22 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2020-07-21 · Exercise / conversion · Acquired 300 · Balance 221,167 Row 2 · 2020-07-21 · Sale · Disposed 300 · Balance 220,867 F1: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 300 shares in multiple trades at prices ranging from $65.00 to $65.11. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2020-07-21 · Exercise / conversion · Acquired 3,021 · Balance 223,888 Row 4 · 2020-07-21 · Sale · Disposed 3,021 · Balance 220,867 F2: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,021 shares in multiple trades at prices ranging from $65.00 to $65.31. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2020-07-22 · Exercise / conversion · Acquired 8,426 · Balance 229,293 Row 6 · 2020-07-22 · Sale · Disposed 400 · Balance 228,893 F3: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 400 shares in multiple trades at prices ranging from $65.16 to $65.82. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2020-07-22 · Sale · Disposed 4,228 · Balance 224,665 F4: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 4,228 shares in multiple trades at prices ranging from $66.21 to $67.19. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2020-07-22 · Sale · Disposed 3,798 · Balance 220,867 F5: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,798 shares in multiple trades at prices ranging from $67.21 to $67.80. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2020-07-22 · Exercise / conversion · Acquired 3,774 · Balance 224,641 Row 10 · 2020-07-22 · Sale · Disposed 1,151 · Balance 223,490 F6: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,151 shares in multiple trades at prices ranging from $65.76 to $66.75. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 11 · 2020-07-22 · Sale · Disposed 2,623 · Balance 220,867 F7: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 2,623 shares in multiple trades at prices ranging from $66.79 to $67.64. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 12 · 2020-07-22 · Exercise / conversion · Acquired 30,772 · Balance 251,639 Row 13 · 2020-07-22 · Sale · Disposed 1,380 · Balance 250,259 F8: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,380 shares in multiple trades at prices ranging from $65.00 to $65.92. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 14 · 2020-07-22 · Sale · Disposed 12,217 · Balance 238,042 F9: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 12,217 shares in multiple trades at prices ranging from $66.03 to $67.02. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 15 · 2020-07-22 · Sale · Disposed 17,175 · Balance 220,867 F10: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 17,175 shares in multiple trades at prices ranging from $67.04 to $67.94. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $11.46 · Expires 2026-02-24 | Direct | 8,426 |
Reported balance
After 2020-07-21 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2020-07-21 · Exercise / conversion · Disposed 300 · Balance 8,426 F11: Fully vested as of the date hereof. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2028-02-26 | Direct | 98,358 |
Reported balance
After 2020-07-21 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2020-07-21 · Exercise / conversion · Disposed 3,021 · Balance 98,358 F12: Fully-vested as of the date hereof except for options to purchase 67,586 ordinary shares, which will vest in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $11.46 · Expires 2026-02-24 | Direct | 0 |
Reported balance
After 2020-07-22 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2020-07-22 · Exercise / conversion · Disposed 8,426 · Balance 0 F11: Fully vested as of the date hereof. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $11.46 · Expires 2026-02-24 | Direct | 0 |
Reported balance
After 2020-07-22 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2020-07-22 · Exercise / conversion · Disposed 3,774 · Balance 0 F11: Fully vested as of the date hereof. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2028-02-26 | Direct | 67,586 |
Reported balance
After 2020-07-22 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2020-07-22 · Exercise / conversion · Disposed 30,772 · Balance 67,586 F13: Options to purchase 67,586 ordinary shares will vest and become exercisable in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 300 shares in multiple trades at prices ranging from $65.00 to $65.11. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F2: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,021 shares in multiple trades at prices ranging from $65.00 to $65.31. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F3: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 400 shares in multiple trades at prices ranging from $65.16 to $65.82. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F4: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 4,228 shares in multiple trades at prices ranging from $66.21 to $67.19. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F5: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,798 shares in multiple trades at prices ranging from $67.21 to $67.80. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F6: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,151 shares in multiple trades at prices ranging from $65.76 to $66.75. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F7: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 2,623 shares in multiple trades at prices ranging from $66.79 to $67.64. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F8: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,380 shares in multiple trades at prices ranging from $65.00 to $65.92. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F9: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 12,217 shares in multiple trades at prices ranging from $66.03 to $67.02. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F10: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 17,175 shares in multiple trades at prices ranging from $67.04 to $67.94. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F11: Fully vested as of the date hereof.
F12: Fully-vested as of the date hereof except for options to purchase 67,586 ordinary shares, which will vest in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates.
F13: Options to purchase 67,586 ordinary shares will vest and become exercisable in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2019 Filed Jun 10, 2019 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,999 | $54.79 | $328,661.21 |
DisclosureSEC source: 0001209191-19-035774 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F2 · price: On June 6, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 5,999 shares in multiple trades at prices ranging from $54.49 to $55.14. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,999 | $7.15 | $42,892.85 |
DisclosureSEC source: 0001209191-19-035774 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 17,500 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-035045 · doc4.xml · derivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,013 Underlying: Ordinary Shares · 17,500 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 17,500 | $54.14 | $947,485.00 |
DisclosureSEC source: 0001209191-19-035045 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F2 · price: On June 5, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 17,500 shares in multiple trades at prices ranging from $53.86 to $54.80. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 17,500 | $7.15 | $125,125.00 |
DisclosureSEC source: 0001209191-19-035045 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 17,500 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-034749 · doc4.xml · derivative · entry 8 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,513 Underlying: Ordinary Shares · 17,500 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $53.79 | $10,758.00 |
DisclosureSEC source: 0001209191-19-034749 · doc4.xml · nonDerivative · entry 6 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F5 · price: On June 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 200 shares in multiple trades at prices ranging from $53.74 to $53.84. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 17,300 | $53.11 | $918,854.90 |
DisclosureSEC source: 0001209191-19-034749 · doc4.xml · nonDerivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,874 F4 · price: On June 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 17,300 shares in multiple trades at prices ranging from $52.73 to $53.70. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 17,500 | $7.15 | $125,125.00 |
DisclosureSEC source: 0001209191-19-034749 · doc4.xml · nonDerivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 17,500 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-034749 · doc4.xml · derivative · entry 7 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,013 Underlying: Ordinary Shares · 17,500 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 800 | $52.70 | $42,158.40 |
DisclosureSEC source: 0001209191-19-034749 · doc4.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F3 · price: On June 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 800 shares in multiple trades at prices ranging from $52.65 to $52.83. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 16,700 | $52.09 | $869,969.80 |
DisclosureSEC source: 0001209191-19-034749 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,474 F2 · price: On June 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 16,700 shares in multiple trades at prices ranging from $51.64 to $52.63. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 17,500 | $7.15 | $125,125.00 |
DisclosureSEC source: 0001209191-19-034749 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| May 08, 2019 Filed May 10, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028876 · doc4.xml · derivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2029-05-08 F2 · derivative.exercise_date: Options to buy 20,000 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $71.34 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Ambrogi has been continuously employed by the Company through May 8, 2022. Read SEC document |
| May 08, 2019 Filed May 10, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 91,515 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028876 · doc4.xml · derivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,515 Underlying: Ordinary Shares · 91,515 shares Expires 2029-05-08 F1 · derivative.exercise_date: Options to buy 91,515 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $59.45 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Ambrogi has been continuously employed by the Company through May 8, 2022. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 15,516 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · derivative · entry 12 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,516 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 132 | $47.83 | $6,313.96 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · nonDerivative · entry 9 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F7 · price: On April 2, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 132 shares in multiple trades at prices ranging from $47.81 to $47.84. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 15,384 | $47.24 | $726,724.78 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · nonDerivative · entry 8 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,806 F6 · price: On April 2, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 15,384 shares in multiple trades at prices ranging from $46.80 to $47.71. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 15,516 | $14.37 | $222,964.92 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · nonDerivative · entry 7 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 12,500 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · derivative · entry 11 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,774 Underlying: Ordinary Shares · 12,500 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 21,875 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · derivative · entry 10 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,516 Underlying: Ordinary Shares · 21,875 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,298 | $48.09 | $62,418.22 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · nonDerivative · entry 6 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F5 · price: On April 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,298 shares in multiple trades at prices ranging from $47.94 to $48.25. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,202 | $47.39 | $530,896.39 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · nonDerivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,972 F4 · price: On April 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 11,202 shares in multiple trades at prices ranging from $46.94 to $47.94. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 12,500 | $11.46 | $143,250.00 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · nonDerivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,600 | $48.07 | $76,915.20 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F3 · price: On April 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,600 shares in multiple trades at prices ranging from $47.92 to $48.25. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 20,275 | $47.29 | $958,784.48 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,274 F2 · price: On April 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 20,275 shares in multiple trades at prices ranging from $46.90 to $47.83. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 21,875 | $14.37 | $314,343.75 |
DisclosureSEC source: 0001209191-19-023120 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 29,969 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001209191-19-021301 · doc4.xml · derivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,969 Underlying: Ordinary Shares · 29,969 shares Expires 2029-03-21 F2 · derivative.exercise_date: Options to buy 29,969 ordinary shares will vest and become exercisable in equal installments on each of March 5, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 16,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021301 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F1 · shares: Represents restricted share units that are scheduled to vest on March 5, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 16:35 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,397 | $53.68 | $128,670.96 |
DisclosureSEC source: 0001209191-19-015002 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,305 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:35 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 6,174 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015002 · doc4.xml · derivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,345 Underlying: Ordinary Shares · 6,174 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:35 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 6,174 | $52.90 | $326,604.60 |
DisclosureSEC source: 0001209191-19-015002 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 18:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 12,230 | $53.63 | $655,870.44 |
DisclosureSEC source: 0001209191-19-013683 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,528 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 18:00 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 31,200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013683 · doc4.xml · derivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,199 Underlying: Ordinary Shares · 31,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 18:00 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 31,200 | $53.38 | $1,665,456.00 |
DisclosureSEC source: 0001209191-19-013683 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 21,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-007326 · doc4.xml · derivative · entry 7 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,513 Underlying: Ordinary Shares · 21,000 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 21,000 | $49.53 | $1,040,193.00 |
DisclosureSEC source: 0001209191-19-007326 · doc4.xml · nonDerivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,558 F4 · price: On February 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 21,000 shares in multiple trades at prices ranging from $49.08 to $49.75. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 21,000 | $7.15 | $150,150.00 |
DisclosureSEC source: 0001209191-19-007326 · doc4.xml · nonDerivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 37,500 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-007326 · doc4.xml · derivative · entry 6 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,513 Underlying: Ordinary Shares · 37,500 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,840 | $49.51 | $487,158.72 |
DisclosureSEC source: 0001209191-19-007326 · doc4.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,558 F3 · price: On February 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 9,840 shares in multiple trades at prices ranging from $49.33 to $49.94. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 27,660 | $48.86 | $1,351,495.26 |
DisclosureSEC source: 0001209191-19-007326 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,398 F2 · price: On February 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 27,660 shares in multiple trades at prices ranging from $48.33 to $49.32. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 37,500 | $7.15 | $268,125.00 |
DisclosureSEC source: 0001209191-19-007326 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 54,930 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-003550 · doc4.xml · derivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,391 Underlying: Ordinary Shares · 54,930 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 34,050 | $41.14 | $1,400,817.00 |
DisclosureSEC source: 0001209191-19-003550 · doc4.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,558 F3 · price: On January 10, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 34,050 shares in multiple trades at prices ranging from $41.00 to $41.45. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 20,880 | $40.47 | $844,992.72 |
DisclosureSEC source: 0001209191-19-003550 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,608 F2 · price: On January 10, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 20,880 shares in multiple trades at prices ranging from $40.00 to $40.99. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 54,930 | $14.37 | $789,344.10 |
DisclosureSEC source: 0001209191-19-003550 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 16:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 25,000 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001209191-19-003415 · doc4.xml · derivative · entry 6 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,274 Underlying: Ordinary Shares · 25,000 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 16:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 75,000 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-003415 · doc4.xml · derivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,321 Underlying: Ordinary Shares · 75,000 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 16:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 25,000 | $40.00 | $1,000,000.00 |
DisclosureSEC source: 0001209191-19-003415 · doc4.xml · nonDerivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,558 F2 · price: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 16:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 25,000 | $11.46 | $286,500.00 |
DisclosureSEC source: 0001209191-19-003415 · doc4.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.